Immatics NV (IMTX) Stock Price, Quote & News

Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid t...

Industry: Biotechnology

Sector: Healthcare

Phone: 49 7071 5397 0

Fax: 49 7071 5397 900

Website: www.immatics.com

Address:

Paul-Ehrlich-Strasse 15, Tübingen, Germany

Biotech_Beast Dec. 5 at 9:28 PM

$IMTX still holding calls on this name, data next week and in 2026 too.

0 · Reply

medguy Dec. 5 at 4:08 PM

Looking for bounce $PSN $IMTX $S $IMTX

0 · Reply

Quantumup Dec. 5 at 4:01 PM

Leerink y'day⬆️ $IMTX's PT to $17 from $16 and reiterated at an Outperform rating. $IMCR $IDYA $GILD AZN AMGN $IOVA Here's what Leerink said in its research note: https://x.com/Quantumup1/status/1996972164738691486?s=20

0 · Reply

AAUS1 Dec. 5 at 3:45 PM

$IMTX such a bad timing of news , the stock was breaking out !! Ah !!

2 · Reply

OpenOutcrier Dec. 5 at 2:03 PM

$IMTX (-8.0% pre) Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering https://ooc.bz/l/86459

0 · Reply

TwongStocks Dec. 5 at 11:07 AM

$IMTX Immatics Announces $125 Million Underwritten Offering https://www.globenewswire.com/news-release/2025/12/05/3200531/0/en/Immatics-Announces-125-Million-Underwritten-Offering.html • 12,500,000 shares at $10 • offering is expected to close on December 8, 2025

0 · Reply

AAUS1 Dec. 5 at 3:14 AM

$IMTX 23 ?

0 · Reply

OhioTrader Dec. 5 at 12:26 AM

$IMTX running like somebody knows something 👀

0 · Reply

NJgolfer Dec. 5 at 12:13 AM

$IMTX there's that breakout!

0 · Reply

ArbVinnie Dec. 1 at 2:18 PM

$IMTX mentioned in this article; https://www.biospace.com/drug-development/6-companies-hanging-on-in-cell-therapy?_gl=1*1qvike5*_up*MQ..*_ga*MTU4ODUyMDcxNC4xNzY0NTk3ODIx*_ga_Q90M6MWJZ4*czE3NjQ1OTc4MjEkbzEkZzAkdDE3NjQ1OTc4MjUkajU2JGwwJGgw

0 · Reply

Immatics Announces $125 Million Underwritten Offering

Nov 12, 2025, 7:00 AM EST - 25 days ago

Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps

Oct 27, 2025, 7:00 AM EDT - 5 weeks ago

Immatics Appoints Amie Krause as Chief People Officer

Oct 20, 2025, 10:30 AM EDT - 6 weeks ago

Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium

Oct 10, 2025, 10:25 AM EDT - 2 months ago

Immatics: Multiple Clinical Catalysts In Q4'25 And 2026

Aug 13, 2025, 7:00 AM EDT - 4 months ago

Immatics Announces Second Quarter 2025 Financial Results and Business Update

May 31, 2025, 8:00 AM EDT - 6 months ago

Immatics IMA203 PRAME Cell Therapy Data Presented at 2025 ASCO Annual Meeting Continues to Show Strong Anti-tumor Activity and Durability in Patients with Metastatic Melanoma

May 13, 2025, 7:00 AM EDT - 7 months ago

Immatics Announces First Quarter 2025 Financial Results and Business Update

Apr 23, 2025, 10:00 AM EDT - 8 months ago

Immatics Announces Upcoming Oral and Poster Presentation on IMA203 TCR T-cell Therapy at 2025 ASCO Annual Meeting

Mar 28, 2025, 1:02 PM EDT - 9 months ago

Immatics N.V.: Trading Below Cash, But Not Without Reason

Mar 27, 2025, 7:00 AM EDT - 9 months ago

Immatics Announces Full Year 2024 Financial Results and Business Update

Nov 18, 2024, 7:00 AM EST - 1 year ago

Immatics Announces Third Quarter 2024 Financial Results, Business Update and First Clinical Data on TCER® IMA402 Targeting PRAME

Nov 8, 2024, 5:00 PM EST - 1 year ago

Immatics Announces Multiple Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) on TCR-T Therapy Candidates Targeting PRAME

Oct 11, 2024, 9:11 PM EDT - 1 year ago

Immatics: A Promising TCR Pipeline

Oct 10, 2024, 8:50 PM EDT - 1 year ago

Immatics Announces Pricing of $150 Million Public Offering

Oct 10, 2024, 1:33 PM EDT - 1 year ago

Why Is Cancer-Focused Immatics Stock Trading Lower On Thursday?

Oct 10, 2024, 7:30 AM EDT - 1 year ago

Immatics Announces Proposed $150 Million Public Offering

Oct 10, 2024, 6:30 AM EDT - 1 year ago

Immatics Announces Updated Phase 1b Clinical Data on ACTengine® IMA203 TCR-T Targeting PRAME in Melanoma Patients and Provides Update on Upcoming SUPRAME Phase 3 Trial

Oct 4, 2024, 9:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral and Poster Presentations at the Society for Immunotherapy of Cancer Annual Meeting 2024

Sep 16, 2024, 5:25 AM EDT - 1 year ago

Immatics Presents Clinical Proof-of-Concept Data from Ongoing Phase 1 Dose Escalation Trial with TCR Bispecific Molecule TCER® IMA401 Targeting MAGEA4/8 at ESMO 2024 and Provides Development Update

Sep 6, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Upcoming Oral Presentation at the Society for Melanoma Research Congress 2024

Aug 13, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Second Quarter 2024 Financial Results and Business Update

May 14, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces First Quarter 2024 Financial Results and Business Update

Apr 27, 2024, 10:32 AM EDT - 1 year ago

Immatics: Big Pharma Partners, Intriguing Catalysts Make Buy Case

Mar 21, 2024, 7:00 AM EDT - 1 year ago

Immatics Announces Full Year 2023 Financial Results and Corporate Update

Feb 3, 2024, 7:56 AM EST - 2 years ago

Immatics: Pioneering TCR Therapies In The Fight Against Cancer

Jan 17, 2024, 8:30 PM EST - 2 years ago

Immatics Announces Pricing of $175 Million Public Offering

Jan 17, 2024, 4:01 PM EST - 2 years ago

Immatics Announces Proposed Public Offering

Nov 14, 2023, 7:00 AM EST - 2 years ago

Immatics Announces Third Quarter 2023 Financial Results and Business Update

Nov 8, 2023, 7:00 AM EST - 2 years ago

Immatics Reports Interim Clinical Data from ACTengine® IMA203 and IMA203CD8 TCR-T Monotherapies Targeting PRAME in an Ongoing Phase 1 Trial

Oct 24, 2023, 7:00 AM EDT - 2 years ago

Immatics Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for ACTengine® IMA203 TCR-T Monotherapy

Oct 9, 2023, 1:33 AM EDT - 2 years ago

Analyzing Immatics' Multi-Faceted Investment Case

Sep 12, 2023, 6:50 AM EDT - 2 years ago

Protalix BioTherapeutics Appoints Eliot Richard Forster, Ph.D. as Chairman of its Board of Directors

PLX

Sep 11, 2023, 8:59 AM EDT - 2 years ago

Immatics shares rise on Moderna cancer collaboration

MRNA

Sep 11, 2023, 7:32 AM EDT - 2 years ago

Moderna, Immatics to work jointly on cancer vaccines

MRNA

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Moderna and Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Sep 11, 2023, 7:00 AM EDT - 2 years ago

Moderna & Immatics Announce Strategic Multi-Platform Collaboration to Develop Innovative Oncology Therapeutics

MRNA

Aug 17, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces Second Quarter 2023 Financial Results and Business Update

Aug 10, 2023, 7:00 AM EDT - 2 years ago

Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific IMA402 in Patients with Advanced Solid Tumors

Jul 24, 2023, 6:21 PM EDT - 2 years ago

Immatics: Additional Gains Possible Q4 Of 2023 With Data Update Of IMA203

Jul 24, 2023, 10:00 AM EDT - 2 years ago

Immatics Is Increasingly Becoming Interesting

Jul 24, 2023, 7:56 AM EDT - 2 years ago

Immatics shares jump after investment from Bristol Myers Squibb

BMY

Jul 24, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces $35 Million Equity Investment from Bristol Myers Squibb

May 16, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces First Quarter 2023 Financial Results and Business Update

May 2, 2023, 11:21 AM EDT - 2 years ago

Why Immatics Stock Is Soaring Today

May 2, 2023, 7:00 AM EDT - 2 years ago

Immatics Reports Interim Clinical Data from Ongoing Phase 1b Cohort A Monotherapy with ACTengine® IMA203 TCR-T Targeting PRAME

May 1, 2023, 7:00 AM EDT - 2 years ago

Immatics Announces First Bristol Myers Squibb Opt-in of TCR-T Candidate from Ongoing Multi-target Strategic Collaboration

Mar 21, 2023, 7:31 AM EDT - 2 years ago

Immatics Announces Full Year 2022 Financial Results and Corporate Update

Nov 17, 2022, 7:00 AM EST - 3 years ago

Immatics Announces Third Quarter 2022 Financial Results and Business Update

Oct 10, 2022, 7:37 AM EDT - 3 years ago

Immatics Announces $110 Million Underwritten Offering of Ordinary Shares

Biotech_Beast Dec. 5 at 9:28 PM

$IMTX still holding calls on this name, data next week and in 2026 too.

0 · Reply

medguy Dec. 5 at 4:08 PM

Looking for bounce $PSN $IMTX $S $IMTX

0 · Reply

Quantumup Dec. 5 at 4:01 PM

0 · Reply

AAUS1 Dec. 5 at 3:45 PM

$IMTX such a bad timing of news , the stock was breaking out !! Ah !!

2 · Reply

OpenOutcrier Dec. 5 at 2:03 PM

$IMTX (-8.0% pre) Immatics N.V. Announces Agreement to Sell 12.5 Million Ordinary Shares in Underwritten Offering https://ooc.bz/l/86459

0 · Reply

TwongStocks Dec. 5 at 11:07 AM

0 · Reply

AAUS1 Dec. 5 at 3:14 AM

$IMTX 23 ?

0 · Reply

OhioTrader Dec. 5 at 12:26 AM

$IMTX running like somebody knows something 👀

0 · Reply

NJgolfer Dec. 5 at 12:13 AM

$IMTX there's that breakout!

0 · Reply

ArbVinnie Dec. 1 at 2:18 PM

0 · Reply

AAUS1 Nov. 29 at 7:45 AM

$IMTX Looks a good chance for breakout 🤞

0 · Reply

RunnerSignals Nov. 25 at 8:27 PM

$ANAB $AVAV $BLSH $CALX $IMTX Pipeline magic and tech muscle! Immunology, drones, fiber, and cancer therapies. trading floor excitement on max https://stocksrunner.com/news/2025-11-25-stock-upgrades-today-see-wall-street-boost-confidence

0 · Reply

Biotech_Beast Nov. 24 at 7:37 PM

Noted $REPL and $IMTX (I'm long via calls) in the IOVA article. Melanoma remains competitive. https://seekingalpha.com/article/4847173-iovance-biotherapeutics-several-positives-but-competition-still-threatens

0 · Reply

NJgolfer Nov. 24 at 6:44 PM

$IMTX on verge of breakout

1 · Reply

JarvisFlow Nov. 24 at 4:02 PM

Chardan Capital updates rating for Immatics ( $IMTX ) to Buy, target set at 25.

0 · Reply

JarvisFlow Nov. 19 at 2:28 PM

Mizuho has adjusted their stance on Immatics ( $IMTX ), setting the rating to Outperform with a target price of 19 → 23.

0 · Reply

JarvisFlow Nov. 18 at 2:19 PM

Guggenheim has updated their rating for Immatics ( $IMTX ) to Buy with a price target of 19.

0 · Reply

RedHottie Nov. 17 at 11:15 PM

$IMTX 🔷 $ADAPY IMTX folks — TCR sector update. ADAPY just restructured top-to-bottom and confirmed they’re still working with US WorldMeds on TECELRA/lete-cel/uza-cel transition efforts. Meanwhile, they’re evaluating strategic options for PRAME + CD70. Given IMTX and ADAPY both operate in engineered T-cell oncology, this type of peer reset sometimes redirects volume/attention across the group. Worth noting. 🔬

0 · Reply

Quantumup Nov. 17 at 4:58 PM

BofA⬆️ $IMTX's PT to $14 from $12, reiterated at Buy, and said, PRAME Franchise Continues to Deliver Ahead of SUPRAME Pivotal Data $IMCR $GILD BofA added We continue to like Immatics' PRAME franchise which we'd argue is coming into its own with recent bispecific data adding another key player to the franchise. Immatics remains well-capitalized ($505.8M in cash, runway into 2H27e) to support pipeline developments and reach a potential launch for IMA203 (guided for 2H27e). The nearest-term data catalyst will be IMA203CD8 (to be presented on Dec. 11th at the ESMO Immunooncology Congress) where we'll be looking for enhanced activity/durability to support movement into other PRAME cancers. That said, we'll also be watching updates from IMA402 and IMA401 ahead of the IMA203 pivotal data. We reiterate Buy and lift our PO to $14 (from $12) as we update PoS for bispecific programs and OpEx trends.

0 · Reply

Thestocktraderhubzee Nov. 13 at 11:37 AM

WATCHLIST NOV 13 2025 $IMTX Immatics shares are trading higher after the company announced updated Phase 1a dose escalation data from both product candidates in its TCR Bispecifics pipeline $NGNE Neurogene Announces Updated Interim Clinical Study In Pediatric Group From Its Current Phase 1/2 Trial Evaluating NGN-401 Demonstrates All 8 Patients Showed Functional Gains Across Spectrum Of Disease Severity $JOBY Joby And General Authority Of Civil Aviation Of The Kingdom Of Saudi Arabia Announce Plans For Rapid Deployment Of Joby's electric Air Taxi In The Kingdom $ONON http://Alarm.com Launches Smart ADC-V730 Camera Combining 4MP Video, Color Night Vision, And Real-Time AI Threat Response $ALRM http://Alarm.com Launches Smart ADC-V730 Camera Combining 4MP Video, Color Night Vision, And Real-Time AI Threat Response

0 · Reply

NJgolfer Nov. 13 at 12:26 AM

$IMTX big move today. Up huge since March when I called out how beaten down this was. The pipeline only looks better since that time.

0 · Reply

S_Franconi Nov. 12 at 5:54 PM

$IMTX November 12, 2025 7:00 AM EST Immatics Achieves Clinical Proof-of-Concept of its Next-Generation TCR Bispecific (TCER®) Pipeline with Data on IMA402 (PRAME) and IMA401 (MAGEA4/8) and Announces Next Development Steps https://investors.immatics.com/news-releases/news-release-details/immatics-achieves-clinical-proof-concept-its-next-generation-tcr

0 · Reply

Market Cap	1.24B
Revenue (ttm)	168.63M
Net Income (ttm)	16.47M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	9.77%
Debt to Equity Ratio	0.00

Volume	1,649,400
Avg Vol	851,326
Day's Range	N/A - N/A
Shares Out	121.55M
Stochastic %K	16%
Beta	1.36
Analysts	Strong Sell
Price Target	$18.75